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Objective The present study was designed to investigate
whether genetic polymorphisms of the aryl hydrocarbon
receptor (AHR) signaling pathway are involved in the
molecular basis of essential hypertension (EH).
Methods A total of 2160 unrelated Russian individuals
comprising 1341 EH patients and 819 healthy controls were
recruited into the study. Seven common AHR pathway
single-nucleotide polymorphisms (SNPs) such as
rs2066853, rs2292596, rs2228099, rs1048943, rs762551,
rs1056836, and rs1800566 were genotyped by TaqMan-
based allele discrimination assays.
Results We found that SNP rs2228099 of ARNT is
associated with an increased risk of EH (odds ratio= 1.20
95% confidence interval: 1.01–1.44, P= 0.043) in a dominant
genetic model, whereas polymorphism rs762551 of CYP1A2
showed an association with a decreased risk of disease in a
recessive genetic model (odds ratio= 0.68, 95% confidence
interval: 0.52–0.89, P=0.006). A log-likelihood ratio test
enabled identification of epistatic interaction effects on EH
susceptibility for all SNPs. MB-MDR analysis showed that
cigarette smoking, rs1048943, rs762551, rs1056836, and
rs2228099 were significant contributing factors in 19, 18, 13,
13, and 11 interaction models, respectively. The best MDR
model associated with EH risk included rs1048943,
rs762551, rs1056836, and cigarette smoking (cross-
validation consistency 100%, prediction error 45.7%,
Ppermutation< 0.0001). The mRNA expression and in-silico
function prediction analyses have confirmed a regulatory
potential for a majority of SNPs associated with EH
susceptibility.
Conclusion Our pilot study was the first to show that
gene–gene and gene–environment interactions in the AHR
signaling pathway represent important determinants for the
development of EH, and the pathway may become an
attractive target for a pharmacological intervention in
hypertensive patients in the future. Pharmacogenetics and
Genomics 27:57–69 Copyright © 2017 Wolters Kluwer
Health, Inc. All rights reserved.
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Introduction
Hypertension is a major health burden because of its high
prevalence and associated increased rates of morbidity,
mortality, and disability from cardiovascular disease and
stroke worldwide [1,2]. It has been estimated that almost
28% of the world’s adult population has uncontrolled
hypertension [3] and the global burden of disease will
increase to more than 1.5 billion by 2025 [4]. In most
cases, the etiology of hypertension remains unclear,
which is the reason for the definition of the disease as
essential hypertension (EH). The mechanisms involved
in the regulation of blood pressure (BP) in human
populations are complex and are likely modulated by
tight interactions between genetic and environmental
factors, suggesting a multifactorial nature of hypertension
[5,6].
Genome-wide association scans and candidate gene studies
have successfully identified a number of common genetic
variants influencing BP variation and hypertension suscept-
ibility in ethnically diverse populations [7–10]. Despite the
progress in hypertension genomics, the difficult task remains
in the bridging of genetic findings into the clinic. Such a
translation, on the one hand, takes considerable time to move
from a identified gene target to an approved marketed drug;
on the other, the effect sizes of genome-wide association
scans identified BP loci are relatively small and the advantage
of their utilization in the clinical practice is not clear [11].
Although adequate drug treatment and control of hyperten-
sion result in reduced morbidity and mortality [12,13], the
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findings obtained by pharmacogenomic studies of anti-
hypertensive drugs are also far from being utilized in the
clinic [14–16]. Thus, much of the heritability of BP, hyper-
tension, and efficacy of antihypertensive treatment remain
unexplained, highlighting the need for further identification
of major genetic and environmental factors responsible for the
global epidemic of the disease.
A huge number of studies have shown a positive relationship
between incident hypertension and ambient air pollution
[17–24]. A rapidly growing body of evidences suggests that
airborne polycyclic aromatic hydrocarbons (PAHs) may
represent an important group of organic toxic chemicals with a
potentially causative role for hypertension [25–29]. PAHs are a
group of pollutants prevalent widely in the environment,
formed during incomplete combustion of organic materials
such as coal and petroleum product combustion, cigarette
smoking, food cooking, and industrial activities [30].
Individuals exposed to PAHs defend themselves against
intracellular damage by activating the transcription of genes
involving in the aryl hydrocarbon receptor (AHR) signal
transduction cascade that defends the host, removing and
metabolizing the toxicant [31,32]. Figure 1 summarizes the
organization and functions of the AHR signaling pathway.
AHR is a ligand-dependent transcription factor that regulates
the induction of the phase I and II xenobiotics-metabolizing
enzymes (XMEs), and thus mediating most of the toxic and
carcinogenic effects of PAHs as well as polyhalogenated
hydrocarbons (dioxins, furans) and polychlorinated biphenyls
[37,38]. The basic helix–loop–helix proteins AHR, aryl
hydrocarbon receptor nuclear translocator (ARNT) and aryl
hydrocarbon receptor repressor (AHRR), and regulated XMEs
represent the AHR signaling pathway, the adaptive xenobiotic
stress system that recognizes putatively toxic compounds and
triggers their detoxification and elimination [39].
Several common single-nucleotide polymorphisms (SNPs) in
genes involved in the AHR signaling pathway have been
identified and shown to determine interindividual differences
in the ability to activate and detoxify PAHs [40–44]. A single
study, which investigated two SNPs of the AHR pathway,
observed that an interaction between the CYP1A1 T3801C
and AHR G1661A polymorphisms is associated with BP [45].
A few studies in humans have shown an association between
genes encoding AHR regulated XMEs such as CYP1A1,
CYP1A2, and CYP1B1 and hypertension susceptibility
[46–48]. To our knowledge, no studies have been carried out
so far to investigate a comprehensive contribution of AHR
pathway genes toward the development of EH. Therefore,
the aim of our pilot study was to investigate whether common
polymorphisms of the AHR signaling pathway are compre-
hensively involved in the molecular basis of EH.
Methods
Study population
The study protocol was approved by the Ethical Review
Committee of Kursk State Medical University and written
informed consent was obtained from each participant
before enrollment. A total of 2160 unrelated individuals of
Russian origin from of the Central Russia (predominantly
from Kursk region) comprising 1341 EH patients and 819
healthy individuals with normal BP were recruited at
Cardiology Clinics of Kursk Regional Clinical Hospital
and Neurology Clinics of Kursk Emergency Medicine
Hospital as described previously [49,50]. EH was diag-
nosed by qualified cardiologists. Patients were defined as
hypertensive according to WHO criteria or if they had a
history of receiving any antihypertensive drug. All EH
patients had no clinical signs, symptoms, and laboratory
findings suggestive of secondary hypertension. Study
patients completed a questionnaire on conventional
demographic characteristics and also smoking status,
which was considered a measure of individual exposure to
PAHs. The baseline characteristics of the study partici-
pants are shown in Table 1. EH patients were matched to
healthy controls in terms of sex and age (P> 0.05).
Genetic analysis
Whole-blood samples were collected by venipuncture from
all study participants in EDTA-coated tubes and maintained
at −20°C until processed. Genomic DNA was isolated from
thawed blood samples using a standard phenol/chloroform
procedure. Candidate genes involved in the AHR signaling
pathway were selected on the basis of their involvement in
the pathway using the KEGG Pathway (http://www.genome.
jp/kegg/pathway.html), the Reactome Pathway (http://www.
reactome.org), and PharmGKB (http://www.pharmgkb.org)
databases. The selected AHR pathway genes included AHR
(gene ID 196), ARNT (gene ID 405), AHRR (gene ID
57491), CYP1A1 (cytochrome P450 family 1 subfamily A
member 1, gene ID 1543), CYP1A2 (cytochrome P450
family 1 subfamily A member 2, gene ID 1544), CYP1B1
(cytochrome P450 family 2 subfamily A member 1, gene ID
1545), and NQO1 [NAD(P)H dehydrogenase, quinone 1,
gene ID 1728]. Most commonly studied and potentially
functional SNPs in these genes (minor allele frequency>
5%) such as AHR R554K (rs2066853), AHRR P185A
(rs2292596), ARNT 567C>G (rs2228099), CYP1A1 I462V
(rs1048943), CYP1A2–163C>A (rs762551), CYP1B1, V432L
(rs1056836), and NQO1 P187S (rs1800566) were selected for
the study. Detailed information on the biological function of
the genes and their polymorphisms is present in
Supplementary Table 1 (Supplemental digital content 1,
http://links.lww.com/FPC/B134). The polymorphisms were
genotyped by TaqMan-based allele discrimination assays on
the CFX96 Real-Time PCR Detection System (Bio-Rad
Laboratories, Hercules, California, USA) on the basis of the
protocols published in the literature (sequences of TaqMan-
probes and primers sets with references used in this study
are listed in Supplementary Table 2, Supplemental digital
content 2, http://links.lww.com/FPC/B135). The average call
rate for genotyping was 97.6%. As quality controls, about 5%
of the samples were selected randomly in a blinded manner
to case–control status and their repeated genotyping yielded
100% reproducibility.
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To evaluate genotype–phenotype correlations, we used
the genotype and mRNA expression data available for 60
HapMap European individuals and the SNPexp v1.2
online tool (http://app3.titan.uio.no/biotools/tool.php?app=
snpexp). The functionality of selected SNPs was also
assessed in silico using the SNP Function Prediction tool
developed by Xu and Taylor [51] and available online at
the SNPinfo Web Server (https://snpinfo.niehs.nih.gov/
snpinfo/snpfunc.htm).
Data analysis
The sample size for the study groups was estimated using
statistical power calculations for a χ2-test on the basis of
allele and genotype frequencies of AHR pathway SNPs
in European populations. An association analysis of the
AHR pathway SNPs with EH risk could detect a differ-
ence of 4–7% in the genotype distributions between the
cases and controls assuming 77–97% power and a 5%
type I error (α= 0.05) on the basis of the sample sizes of
1341 hypertensives and 819 healthy individuals.
Allele frequencies were estimated using the gene-
counting method and the χ2-test was used to identify
significant departures from Hardy–Weinberg equilibrium
(HWE). The distribution of alleles was analyzed by 2× 2
contingency tables, and the distributions of the genotypes
Fig. 1
The organization of the AHR signaling pathway and regulated xenobiotic-metabolizing enzymes [32–36]. The ligand binding to and following activation of
AHR is the initial step in the mode of action for a variety of biological and toxicological responses to TCDD and dioxin-like compounds of the environment.
AHR recognizes the presence of xenobiotics in the cytoplasm, and then acts to induce XMEs to facilitate the elimination of the foreign compounds. The
main genes of the AHR pathway include the ligand-binding receptor AHR, the AHR nuclear translocator (ARNT), and the AHR regulator (AHRR).
Normally, AHR exists in a dormant state within the cytoplasm in association with proteins Hsp90, XAP2, and p23, which help to correctly fold and stabilize
the AHR and prevent inappropriate trafficking to the nucleus. Upon ligand binding, AHR in the complex is activated by a conformation change and
migrates to the nucleus, where it forms a heterodimer with ARNT, thereby forming a protein complex capable of binding to DNA. The AHR-ARNT complex
binds to the xenobiotic response element (XRE) motifs in enhancers of target genes, thereby inducing the transcription of XMEs such as CYP1A1,
CYP1A2, CYP1B1, and others. AHRR, sharing structural similarities with AHR and ARNT, may compete with the AHR to bind XRE. The AHRR–ARNT
heterodimer is capable of binding with XRE, but without transactivate gene expression. However, AHRR may enhance the release of AHR–ARNT complex
from the XRE sequence, resulting in inhibition of AHR-mediated signal transduction and, therefore, protecting against XME-mediated cardiotoxicity. AHR,
aryl hydrocarbon receptor; Pol I, DNA polymerase I; TCDD, 2,3,7,8, tetrachlorodibenzo-p-dioxin; XME, xenobiotics-metabolizing enzyme.
Table 1 Baseline characteristics of the study groups
Baseline characteristics Controls (n=819) [n (%)] Essential hypertension patients (n=1341) [n (%)] P-value
Age (mean ±SD) 56.2 ±8.9 56.4 ±10.2 0.63
Male 393 (49.1) 675 (52.9) 0.09
BMI (mean ±SD) (kg/m2) 27.1 ±7.4 27.7 ±6.8 0.06
Antihypertensive medication use – 979 (73.0) –
Positive family history of hypertension 422 (57.3) 717 (64.0) 0.003*
Number of smokers (ever/never) 314 (39.0) 407 (31.5) 0.001*
*Bold values indicate statistically significant difference between the groups.
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and their combinations between patients and controls
were evaluated by logistic regression analysis. Categorical
variables such sex, smoking status, and family history of
hypertension were also compared using the χ2-test. These
statistics were calculated using STATISTICA software
for Windows 10.0 (StatSoft Inc., Tulsa, Oklahoma, USA).
The association between genotypes and EH risk was
determined by multiple logistic regression analysis to
calculate odds ratios (ORs) with 95% confidence intervals
(CIs) and adjusted for age and sex. Pairwise gene–gene
interactions were evaluated using the log-likelihood ratio
test (LRT) assuming codominant, dominant, recessive,
and overdominant models and adjusted for age and sex.
The calculations were carried out using the SNPassoc
package for R [52].
As the dimensionality of the data is known to be the central
problem in statistical analysis for gene–gene interactions in
common disease [53,54], we used the multifactor dimen-
sionality reduction method (MDR) [55–57], a data-mining
bioinformatic approach, to investigate high-order gene–gene
and gene–environment interactions in EH. We applied the
model-based multifactor dimensionality reduction method
(MB-MDR) [58] implemented in the mbmdr package for R
[59] in our dataset. It is an extension of the popular MDR
method, which enables the measurement of the association
between multilocus genotypes and the phenotype, and
provides a set of statistically significant interactions instead
of a single best model. In the first step of the MB-MDR
algorithm, association tests of each multilocus genotype
combination and environment risk factor (cigarette smoking)
with EH risk are performed using logistic regression. Then,
each multilocus genotype was assigned to three risk cate-
gories: high, low, and no risk, respectively. In the second
step of the algorithm, the association of pooled genotypes in
low-risk and high-risk categories was evaluated through
logistic regression analysis. Wald statistics were used to
explore the significance of results and the interactionmodels
were ranked by adjusted P-values in the third step. Then,
the most significant high-order interaction between the
predictors and EH risk was considered the best model and
adjusted for multiple testing through 1000 permutations.
Finally, we selected the best most promising interaction for
further evaluation by the conventional MDR analysis
(MDR 3.0.2, http://sourceforge.net/projects/mdr/) to assess the
model’s cross-validation consistency and prediction error.
Permutation testing was used to test the significance of the
reported measure of prediction accuracy and cross-validation
consistency. A generalized linear model was used for the
genotype–phenotype correlation analysis to evaluate the
differences in the relative mRNA expression levels among
carriers with different genotypes.
Results
Association analysis of AHR pathway SNPs with EH
A percentage of a positive family history of hypertension
was significantly greater in EH patients versus healthy
controls (Table 1). In contrast, the number of smokers
was greater among the controls than the EH patients. No
differences were found between the groups in other
demographic characteristics. A departure from HWE was
observed for rs2066853 in both cases (P= 0.03) and
controls (P= 0.03) and also for rs762551 in controls
(P= 0.05). The rest of the SNPs were in agreement with
HWE in the study groups.
Table 2 shows the genotype and allele frequencies of
AHR pathway SNPs. Allele and genotype frequencies in
the studied groups were compatible with those reported
in European populations. SNP rs2228099 showed an
association with an increased risk of EH (OR= 1.20, 95%
CI: 1.01–1.44, P= 0.043) in a dominant model, whereas
polymorphism rs762551 was associated with a decreased
disease risk in a recessive genetic model (OR= 0.68, 95%
CI: 0.52–0.89, P= 0.006). The association of rs762551
with EH risk remained significant after correction for
multiple testing (Pcorrection= 0.05). In the meantime, the
association of SNP rs2228099 with EH did not reach
statistical significance after correction for multiple testing
(Pcorrection= 0.39).
Epistatic interactions between AHR pathway SNPs and
the risk of EH
To assess gene–gene interactions determining hyperten-
sion susceptibility, first, we explored associations between
AHR pathway pairwise genotype combinations and dis-
ease risk. The analysis identified 14 combinations of AHR
pathway genotypes associated with EH risk at P less than
or equal to 0.05. Supplementary Table 3 (Supplemental
digital content 3, http://links.lww.com/FPC/B136) shows the
overall genotype combinations associated with EH risk.
Figure 2 summarizes plots of AHR pathway genotype
combinations associated significantly with EH risk.
Carriers of the 462IV CYP1A1× 432VL CYP1B1 geno-
types (Fig. 2a) had a significantly decreased risk of
hypertension compared with carriers of the rest genotypes
(OR= 0.49, 95% CI: 0.22–0.75, P= 0.001), showing an
epistatic interaction between the loci at an overdominant
genetic model. An overdominant model of the gene–gene
interaction was also observed for the CYP1A2 and ARNT
loci (Fig. 2b). Genotype combination NQO1 187PP×
ARNT 567CG (Fig. 2c) was associated with an increased
EH risk (OR= 1.23, 95% CI: 1.01–1.50, P= 0.04),
whereas the NQO1 187PP×ARNT 567CC/CG genotype
combination showed an association with decreased dis-
ease risk (OR= 0.81, 95% CI: 0.67–0.98, P= 0.03).
In addition, the LRT was performed to look for epistatic
interaction effects between AHR pathway SNPs on
hypertension susceptibility. As can be seen from Table 3,
SNPs rs2228099 and rs762551 showed significant indi-
vidual effects on the risk of EH. The analysis identified
epistatic interactions between ARNT and CYP1A2
(overdominant model, Pinteraction= 0.008), CYP1A1 and
CYP1B1 (dominant model, Pinteraction= 0.001), AHR and
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NQO1 (recessive model, Pinteraction= 0.004), ARNT and
NQO1 (overdominant model, Pinteraction= 0.013), and
AHRR and CYP1A1 (recessive model, Pinteraction= 0.041).
High-order gene–gene and gene–environment
interactions in hypertension susceptibility
The MB-MDR method was applied to the dataset to inves-
tigate high-order gene–gene and gene–environment interac-
tions contributing toward hypertension. Two-order, three-
order, and four-order interaction models among seven SNPs
and smoking status were analyzed and then adjusted for age
and sex. Table 4 shows the best AHR pathway gene–gene
and gene–smoking interactions associated significantly with
the risk of hypertension. Cigarette smoking, rs1048943,
rs762551, rs1056836, and rs2228099 were included as sig-
nificant contributing factors in 19, 18, 13, 13, and 11 interac-
tion models, respectively (a detailed list of all 27 interaction
models is shown in Supplementary Table 4, Supplemental
digital content 4, http://links.lww.com/FPC/B137).
High-order gene–gene and gene–environment interactions
obtained by the conventional MDR method are shown in
Table 5 and Fig. 3. The best interaction model associated
with the risk of EH included rs1048943 (CYP1A1), rs762551
(CYP1A2), rs1056836 (CYP1B1), and cigarette smoking
(Wald statistic=31.51, Ppermutation<0.001). The interaction
between rs1048943, rs762551, rs1056836, and cigarette
smoking showed the highest cross-validation consistency
(100%) and the lowest prediction error (45.7%). The den-
drogram (Fig. 3b) shows a complex pattern of gene–gene
and gene–environment interactions determining EH sus-
ceptibility. Cigarette smoking and rs762551 had the highest
degree of redundancy in their interactions and were also
found to interact with rs1056836 in the same manner, but to
a lesser degree. In the interaction graph (Fig. 3c), cigarette
smoking and rs762551 eliminated 0.48 and 0.36% of class
entropy, respectively, thereby having the largest univariate
effects. A substantial percentage of entropy (0.11%) was
explained by rs762551 and smoking, indicating a redundant
(antagonistic) interaction between them. SNPs rs1048943
and rs1056836 showed relatively small percentages
of entropy when considered independently (0.03 and
0.11%, respectively), whereas a large percentage of entropy
was explained by their interactions with smoking and
rs762551.
Table 2 Genotype and allele frequencies of AHR pathway genes in EH patients and controls
Gene, polymorphism Genotype, allele Controls (n=819) [n (%)]a EH patients (n=1341) [n (%)]a P-value OR (95% CI)b P-value ORadj (95% CI)
c
AHR, R554K (rs2066853) 554RR 658 (80.6) 1044 (79.0) 0.63 0.64
554RK 142 (17.4) 252 (19.1) 1.12 (0.89–1.40) 1.12 (0.89–1.40)
554KK 16 (2.0) 26 (2.0) 1.02 (0.55–1.92) 1.00 (0.53–1.88)
554K 0.107 0.114 0.50
1.07 (0.88–1.31)
–
AHRR, P185A (rs2292596) 185PP 254 (31.4) 403 (31.2) 0.75 0.76
185PA 408 (50.4) 636 (49.3) 0.98 (0.80–1.20) 0.98 (0.81–1.20)
185AA 147 (18.2) 251 (19.5) 1.08 (0.83–1.39) 1.08 (0.83–1.39)
185A 0.565 0.558 0.69
0.98 (0.86–1.11)
–
ARNT, 567C>G (rs2228099) 567CC 344 (43.2) 501 (38.8) 0.14 0.12
567CG 351 (44.0) 618 (47.9) 1.21 (1.00–1.46) 1.21 (1.00–1.47)
567GG 102 (12.8) 172 (13.3) 1.16 (0.87–1.53) 1.17 (0.88–1.55)
567G 0.348 0.373 0.11
1.11 (0.98–1.27)
–
CYP1A1, I462V (rs1048943) 462II 691 (85.6) 1145 (86.6) 0.82 0.83
462IV 112 (13.9) 171 (12.9) 0.92 (0.71–1.19) 0.92 (0.71–1.19)
462VV 4 (0.5) 6 (0.5) 0.91 (0.25–3.22) 0.97 (0.27–3.46)
462V 0.074 0.069 0.50
0.92 (0.72–1.17)
–
CYP1A2, −163C>A (rs762551) −163AA 387 (47.3) 635 (47.6) 0.02 0.015
−163AC 322 (39.3) 571 (42.8) 1.08 (0.90–1.30) 1.09 (0.90–1.31)
−163CC 110 (13.4) 128 (9.6) 0.71 (0.53–0.94) 0.71 (0.53–0.94)
154C 0.330 0.311 0.19
0.92 (0.80–1.05)
–
CYP1B1, V432L (rs1056836) 432VV 278 (33.9) 424 (31.8) 0.56 0.60
432VL 390 (47.6) 651 (48.8) 1.09 (0.90–1.33) 1.09 (0.90–1.33)
432LL 151 (18.4) 260 (19.5) 1.13 (0.88–1.45) 1.12 (0.87–1.44)
432L 0.422 0.439 0.30
1.07 (0.94–1.21)
–
NQO1, P187 S (rs1800566) 187PP 506 (63.0) 836 (62.7) 0.51 0.51
187PS 252 (31.4) 437 (32.8) 1.05 (0.87–1.27) 1.04 (0.86–1.26)
187SS 45 (5.6) 61 (4.6) 0.82 (0.55–1.22) 0.82 (0.55–1.22)
187S 0.212 0.208 0.75
0.98 (0.84–1.14)
–
AHR, aryl hydrocarbon receptor; CI, confidence interval; EH, essential hypertension; OR, odds ratio.
aAbsolute number and percentage of individuals with a particular genotype.
bOR with 95% CIs (codominant genetic model).
cOR with 95% CIs adjusted for age and sex.
Statistically significant P-value with 2 d.f. is represented in bold.
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Then we carried out an MB-MDR analysis stratified by
smoking status, which enabled identification of specific com-
binations of SNPs influencing disease susceptibility in
exposed and unexposed individuals. Table 6 shows the best
models of gene–gene interactions associated with EH in
cigarette smokers and nonsmokers. Detailed data on genotype
combinations associated with EH risk in smokers and non-
smokers are shown in Supplementary Table 5 (Supplemental
digital content 5, http://links.lww.com/FPC/B138). There are
considerable differences in gene–gene interactions between
smokers and nonsmokers, suggesting that exposure to PAHs
is an important factor modifying the association between AHR
pathway genes and hypertension susceptibility.
Genotype–phenotype correlation analysis in AHR
pathway genes
Data on both mRNA expression levels and genotypes for
AHR pathway gene polymorphisms were available from
60 HapMap individuals of European descent. The levels
of ARNT mRNA were correlated with the rs2228099
locus (P= 0.0003, Fig. 4c). AHRR mRNA expression
levels showed an increased trend for rs2292596
(P= 0.007, Fig. 4b). An increased trend was also observed
in CYP1B1 mRNA expression levels and rs1056836
(P= 0.01, Fig. 4f). A board-line correlation (P= 0.08) of
NQO1 mRNA expression levels occurred with the
rs1800566 (Fig. 4g). No significant correlations were
found between both AHR and CYP1A2 expression levels
and SNPs rs2066853 and rs762551, respectively (Fig. 4a
and e). Moreover, an in-silico functional analysis carried
out using the SNP Function Prediction tool has con-
firmed a regulatory potential for the ARNT, AHRR, and
CYP1B1 loci (Supplementary Table 6, Supplemental
digital content 6, http://links.lww.com/FPC/B139). The
CYP1A1 and NQO1 loci also showed a regulatory potential
with a possibly damaging effect on rs1800566. An SNP
Fig. 2
Plots of interactions between AHR pathway genotypes associated with essential hypertension at different genetic models. (a) CYP1A1 × CYP1B1
interactions; (b) CYP1A2 × ARNT interactions; (c) NQO1 × ARNT interactions. AHR, aryl hydrocarbon receptor; CI, confidence interval; ns, not significant.
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rs762551 is located at binding sites for transcription fac-
tors such as, for instance, general transcription factor IIIA
(V$AP2ALPHA_01) and paired box gene 2 (V
$PAX2_01), suggesting a functional significance of the
CYP1A2 polymorphism.
Discussion
In our pilot study, we investigated whether common
polymorphisms of the AHR signaling pathway, an
inherited determinant for PAH-mediated cardiovascular
toxicity, are comprehensively involved in the molecular
Table 3 Epistatic interactions between AHR pathway SNPs in EH
SNPs Genetic models
AHR
rs2066853
AHRR
rs2292596
ARNT
rs2228099
CYP1A1
rs1048943
CYP1A2
rs762551
CYP1B1
rs1056836
NQO1
rs1800566
AHR rs2066853 Сodominant 0.644 0.746 0.838 0.320 0.483 0.874 0.017
Dominant 0.379 0.738 0.577 0.476 0.863 0.753 0.166
Recessive 0.944 0.643 0.281 – 0.886 – 0.004*
Overdominant 0.348 0.346 0.706 0.468 0.589 0.433 0.065
AHRR rs2292596 Сodominant 0.802 0.759 0.970 0.255 0.257 0.587 0.466
Dominant 0.967 0.930 0.606 0.960 0.383 0.494 0.102
Recessive 0.992 0.468 0.966 0.041 0.105 0.252 0.279
Overdominant 0.647 0.626 0.674 0.523 0.320 0.699 0.319
ARNT rs2228099 Сodominant 0.824 0.750 0.124 0.584 0.041 0.696 0.041
Dominant 0.605 0.753 0.043 0.161 0.012 0.287 0.409
Recessive 0.874 0.949 0.702 0.805 0.134 0.500 0.157
Overdominant 0.545 0.752 0.083 0.496 0.008* 0.829 0.013*
CYP1A1 rs1048943 Сodominant 0.760 0.736 0.807 0.833 0.944 0.002 0.530
Dominant 0.470 0.923 0.521 0.549 0.795 0.001* 0.380
Recessive 0.999 0.977 0.973 0.974 0.416 0.210 0.641
Overdominant 0.459 0.465 0.501 0.547 0.983 0.003 0.267
CYP1A2 rs762551 Сodominant 0.672 0.665 0.122 0.798 0.014 0.247 0.120
Dominant 0.929 0.999 0.915 0.701 0.912 0.418 0.969
Recessive 0.936 0.414 0.679 0.927 0.005 0.058 0.411
Overdominant 0.375 0.518 0.080 0.552 0.097 0.980 0.879
CYP1B1 rs1056836 Сodominant 0.705 0.808 0.448 0.855 0.510 0.599 0.864
Dominant 0.435 0.908 0.207 0.574 0.861 0.321 0.778
Recessive 0.987 0.582 0.678 0.970 0.457 0.600 0.597
Overdominant 0.607 0.712 0.467 0.678 0.648 0.605 0.451
NQO1 rs1800566 Сodominant 0.599 0.753 0.500 0.748 0.550 0.640 0.502
Dominant 0.941 0.967 0.967 0.882 0.965 0.893 0.915
Recessive 0.909 0.497 0.697 0.690 0.333 0.697 0.278
Overdominant 0.561 0.563 0.554 0.624 0.590 0.564 0.539
Gene–gene interactions are evaluated using SNPassoc package for R [52].
The upper part of the matrix includes the P-values for epistatic interactions evaluated using the log-likelihood ratio (LRT) test. The diagonal includes the P-values from LRT
for the crude effect of each SNP. The lower triangle includes the P-values from LRT comparing the two-SNP additive likelihood with the best of the single-SNP models.
P-values are adjusted for age and sex.
AHR, aryl hydrocarbon receptor; EH, essential hypertension; SNP, single-nucleotide polymorphism.
Statistically significant P-values for SNP–SNP interactions are in bold.
*Most significant P-values for a particular model are indicated in bold.
Table 4 Best gene–gene and gene–smoking interactions associated significantly with the risk of EHa
G×G/G×E interaction models NH β H WH NL β L WL Pperm
Two-order interaction models
1 CYP1A1 rs1048943× smoking 1 0.263 7.79 2 -0.342 12.28 0.003
2 CYP1A2 rs762551× smoking 2 0.323 11.83 2 −0.390 12.08 0.003
3 CYP1A2 rs762551×ARNT rs2228099 1 0.422 12.53 1 −0.598 7.66 0.011
Three-order interaction models
1 CYP1A1 rs1048943×CYP1B1 rs1056836× smoking 2 0.277 8.10 2 −0.608 22.12 <0.001
2 CYP1A1 rs1048943×CYP1A2 rs762551×CYP1B1 rs1056836 0 NA NA 4 −0.636 21.26 0.001
3 ARNT rs2228099×NQO1 rs1800566× smoking 1 0.264 4.42 4 −0.567 19.04 0.003
Four-order interaction models
1 CYP1A1 rs1048943×CYP1A2 rs762551×CYP1B1 rs1056836× smoking 2 0.345 7.49 4 −0.896 31.51 <0.001
2 ARNT rs2228099×CYP1A1 rs1048943×CYP1B1 rs1056836× smoking 1 0.537 5.02 4 −0.617 22.07 0.007
3 ARNT rs2228099×CYP1A1 rs1048943×NQO1 rs1800566× smoking 1 0.274 4.21 3 −0.845 19.15 0.008
Models are obtained using the model-based multifactor dimensionality reduction method, MB-MDR package for R [59].
β H, regression coefficient for high-risk exposition in the step 2 analysis; β L, regression coefficient for low-risk exposition in the step 2 analysis; EH, essential hypertension;
NA, not available; NH, number of significant high-risk genotypes in the interaction; NL, number of significant low-risk genotypes in the interaction; Pperm, permutation
P-value for the interaction model. The models were adjusted for age and sex; WH, Wald statistic for the high-risk category; WL, Wald statistic for the low-risk category.
aThe full list of statistically significant models for gene–gene and gene–smoking interactions is presented in Supplementary Table 1 (Supplemental digital content 1, http://
links.lww.com/FPC/B134).
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basis of EH. The study showed for the first time that
polymorphic genes for the AHR pathway are important
determinants of genetic susceptibility to EH. We found
that SNP rs762551 of CYP1A2 is associated with a
decreased risk of EH. CYP1A2 is a PAHs-induced cyto-
chrome P450 enzyme metabolizing xenobiotics such as
PAHs, caffeine, aflatoxin B1, and acetaminophen [33].
Polymorphism rs762551 is known to influence caffeine
metabolism and has been found to be associated with the
risk of myocardial infarction [60], BP variation, and
hypertension [61]. This polymorphism is known to be in
a linkage disequilibrium (LD) with an SNP rs1378942
Table 5 Cross-validation statistics for best models of gene–gene and gene–smoking interactions in EH
G×G/G×E interaction models OR (95% CI)
Testing balanced
accuracy
Cross-validation
consistency Pperm
Two-order interaction models
1 CYP1A1 rs1048943× smoking 1.53 (1.28–1.83) 0.543 10/10 <0.0001
2 CYP1A2 rs762551× smoking 1.46 (1.23–1.74) 0.539 10/10 <0.0001
3 CYP1A2 rs762551×ARNT rs2228099 1.38 (1.16–1.63) 0.513 10/10 0.0003
Three-order interaction models
1 CYP1A1 rs1048943×CYP1B1 rs1056836× smoking 1.86 (1.52–2.27) 0.530 10/10 <0.0001
2 CYP1A1 rs1048943×CYP1A2 rs762551×CYP1B1 rs1056836 2.18 (1.70–2.79) 0.503 10/10 <0.0001
3 ARNT rs2228099×NQO1 rs1800566× smoking 1.66 (1.40–1.97) 0.529 10/10 <0.0001
Four-order interaction models
1 CYP1A1 rs1048943×CYP1A2 rs762551×CYP1B1
rs1056836× smoking
1.89 (1.59–2.26) 0.525 10/10 <0.0001
2 ARNT rs2228099×CYP1A1 rs1048943×CYP1B1
rs1056836× smoking
1.94 (1.63–2.31) 0.512 10/10 <0.0001
3 ARNT rs2228099×CYP1A1 rs1048943×NQO1
rs1800566× smoking
1.85 (1.56–2.20) 0.515 10/10 <0.0001
Models are obtained using the multifactor dimensionality reduction method, version 3.0.2.
CI, confidence interval; OR, odds ratio; Pperm, permutation P-value for the interaction model.
Fig. 3
High-order gene–gene (G×G) and gene–environment (G×E) interaction analyses for the AHR pathway SNPs in essential hypertension (data
obtained by Multifactor Dimensionality Reduction package, version 3.0.2). (a) Cross-validation statistics for the best G×E interaction models
underlying essential hypertension susceptibility. The best four-order interaction model with the maximum cross-validation consistency and the
minimum prediction error is indicated in bold. (b) Interaction dendrogram. The lines comprise a spectrum of lines representing a continuum from
synergy to redundancy of G×G and G×E interactions with a variable strength. Brown lines represent the midway point between synergy and
redundancy (additive interaction). On the redundancy end of the spectrum, the highest degree is represented by blue, with a lesser degree
represented by green. The synergy lines range from red, representing a high degree of synergism (not present in the dendrogram), to orange,
representing a lower degree of synergism. (c) Interaction entropy graph. Each SNP is shown in a rectangle box with the percent of entropy (main
effect). Two-way G×G and G×E interactions are shown as color lines accompanied by a percent of entropy (interaction effect). CI, confidence
interval; MDR, multifactor dimensionality reduction; OR, odds ratio; Pperm, permutation P-value for the interaction model; SNP, single-nucleotide
polymorphism.
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(r2= 0.63, HapMap CEU), located in the gene cluster
including the CYP1A2 gene, showed the strongest asso-
ciation (P= 1× 10−23) with diastolic BP in a sample of
34 433 patients of European ancestry [46]. Furthermore,
the relationship between rs762551 and hypertension risk
was shown in the study of Guessous et al. [47], who
observed that this negative association occurred in non-
smokers and is modified by reported caffeine intake.
Thus, the present study provided additional evidence
that CYP1A2 is an important susceptibility gene for EH.
Table 6 Best models of gene–gene interactions associated with EH stratified by cigarette smoking
G×G interaction models NH β H WH NL β L WL Pperm
Two-order, three-order, and four-order interaction models in smokers
1 CYP1A1 rs1048943×CYP1B1 rs1056836 1 0.434 5.98 2 −0.499 9.93 0.014
2 ARNT rs2228099×CYP1A1 rs1048943 0 NA NA 1 −0.952 8.20 0.03
3 ARNT rs2228099×CYP1A2 rs762551 0 NA NA 1 −1.232 8.25 0.05
4 CYP1A1 rs1048943×CYP1A2 rs762551×CYP1B1 rs1056836 1 0.440 3.08 4 −0.795 20.02 <0.002
5 ARNT rs2228099×CYP1A1 rs1048943×CYP1A2 rs762551 0 NA NA 2 −1.520 15.04 0.004
6 CYP1A1 rs1048943×CYP1B1 rs1056836×NQO1 rs1800566 1 0.364 3.04 3 −1.344 14.77 0.01
7 AHR rs2066853×CYP1A1 rs1048943×CYP1A2 rs762551×CYP1B1 rs1056836 1 0.507 3.75 3 −1.637 19.81 0.004
8 ARNT rs2228099×CYP1A1 rs1048943×CYP1A2 rs762551×CYP1B1 rs1056836 0 NA NA 3 −1.988 16.02 0.03
9 ARNT rs2228099×AHRR rs2292536×CYP1A1 rs1048943×NQO1 rs1800566 1 0.631 4.401 4 −0.951 15.25 0.034
Two-order, three-order, and four-order interaction models in nonsmokers
1 ARNT rs2228099×CYP1A2 rs762551 1 0.460 8.45 1 −0.254 2.83 0.043
2 CYP1A2 rs762551×NQO1 rs1800566 0 NA NA 2 −0.658 8.61 0.049
3 ARNT rs2228099×CYP1A2 rs762551× CYP1B1 rs1056836 3 0.580 10.45 3 −0.826 12.39 0.096
4 ARNT rs2228099×AHRR rs2292536×CYP1B1 rs1056836 0 NA NA 3 −0.697 11.80 0.126
5 AHR rs2066853×ARNT rs2228099×AHRR rs2292536×CYP1B1 rs1056836 0 NA NA 5 −0.847 21.41 0.016
6 ARNT rs2228099×CYP1A2 rs762551× CYP1B1 rs1056836×NQO1 rs1800566 2 1.216 7.41 6 −0.769 22.00 0.022
7 AHR rs2066853×ARNT rs2228099×CYP1A2 rs762551×CYP1B1 rs1056836 2 0.772 6.27 5 −0.786 19.84 0.04
Models are obtained using the model-based multifactor dimensionality reduction method.
β H, regression coefficient for high-risk exposition in the step 2 analysis; β L, regression coefficient for low-risk exposition in the step 2 analysis; EH, essential hypertension;
NA, not available; NH, number of significant high-risk genotypes in the interaction; NL, number of significant low-risk genotypes in the interaction; Pperm, permutation
P-value for the interaction model; WH, Wald statistic for the high-risk category; WL, Wald statistic for the low-risk category.
Fig. 4
The relative expression levels of AHR pathway genes mRNA by different genotypes in 60 HapMap individuals of European descent. Expression
profiles were analyzed by the HumanWG-6 Expression BeadChip. The effects of SNPs such as (a) AHR rs2066853, (b) AHRR rs2292596, (c)
ARNT rs2228099, (d) CYP1A1 rs1048943, (e) CYP1A2 rs762551, (f) CYP1B1 rs1056836, and (g) NQO1 rs1800566 on mRNA levels of
corresponding genes are evaluated by generalized linear models (GLMs). Absence of carriers for 462VV CYP1A1 genotypes in this HapMap sample
did not enable the evaluation of the correlation analysis for rs1048943. NA, not available.
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The present study was the first to show that polymorphism
rs2228099 of the ARNT gene could be a novel suscept-
ibility gene to hypertension. Although association of the
SNP with the risk of EH did not reach statistical sig-
nificance after correction for multiple testing, rs2228099 in
combinations with other AHR pathway SNPs showed
combined effects on EH risk. Like AHR, the AHR
translocator is a member of the basic helix–loop–helix
transcription protein superfamily, which is necessary for
dimerization with AHR [37,39]. ARNT associates with
ligand-bound AHR to form a protein complex for binding
to the xenobiotic response element in enhancers of target
genes such as those encoding XMEs as well as genes
associated with oxidative stress, fat metabolism and trans-
port, and cell proliferation [62]. Besides participation in the
AHR signaling, ARNT is also known as hypoxia-inducible
factor-1β, a transcriptional factor for vascular endothelial
cells that regulates genes involved in response to hypoxia
[63], a pathological process that plays a role in the patho-
genesis of hypertension. SNP rs2228099 represents a
synonymous change Val–Val (C>G) at codon 189 in exon
7 of the ARNT gene. No functional information is available
for this polymorphism in dbSNP (http://www.ncbi.nlm.nih.
gov/projects/SNP/). Although this silent SNP is not accom-
panied by the amino acid change in the ARNT protein,
genotypes СG and GG are associated with increased
expression of ARNTmRNA compared with genotype CC,
as it has been shown by the genotype–phenotype corre-
lation analysis in our study. It can be assumed that the
carriers with genotypes СG and GG of ARNT may have
favorable conditions for chronic and persistent activation of
the AHR-ARNT complex resulting in the induction of
XMEs. It cannot be excluded that this polymorphism is in
LD with another yet unidentified functional SNP of ARNT
that could be related to BP variation and/or hypertension
risk. For instance, SNP rs2228099 is in strong LD with
rs12410394, which has been found to be associated with
the risk of colorectal neoplasia [64], the finding pointing
out, on the one hand, the functionality of this SNP, and on
the other, the link of this locus with PAHs-related cancer
susceptibility.
The present study did not observe an association
between EH and the polymorphism of AHR, the main
player and initiator of the signaling cascade. This was not
surprising as AHR, like many such proteins, induced as
part of the stress response to environmental toxicants, is
evolutionarily conserved, and any functional alterations
in the AHR cascade appear to be critical to the evolution,
at least for humans. Apparently, a relatively low rate of
mutations and functional polymorphisms in the AHR
gene [32,40] confers advantages in the bridging between
AHR and its regulated XMEs in maintaining the optimal
setting of the host for adaptive responses to PAHs and
other chemical compounds in the constantly changing
environment.
The MB-MDR method provided additional evidences
indicating that (a) the integrated function of the AHR
pathway genes may promote a coordinated metabolism of
PAH xenobiotics and (b) the AHR signaling pathway loci
and their related XMEs are collectively involved in the
molecular basis of EH. A majority of the modeled
gene–gene interactions associated with EH risk comprise
genes such as ARNT, CYP1A1, CYP1A2, CYP1B1, and
NQO1, findings consistent with the results obtained in the
previous stages of our study. The analysis for gene–gene
interactions carried out using the SNPassoc package
enabled the identification of SNPs exerting significant
effects on disease risk only in combinations. Overall, 27
statistically two-order, three-order, and four-order inter-
action models have been identified to influence the risk
of EH. In particular, significant gene–gene interactions
were found between CYP1A1 and CYP1B1, AHR and
NQO1, ARNT and NQO1, ARNT and CYP1A2, and AHRR
and CYP1A1. These findings point to epistasis; the effect
of one gene may not be disclosed if the effect of another
gene is not considered [57]. Interactions between the loci
suggest that the gene–gene effect on disease risk may be
driven by a true interaction, rather than by the main effect
from each gene alone. Notably, AHR pathway SNPs
showed complex hierarchic interactions, as identified by
the MDR method (Fig. 3). The observed gene–gene
interactions make mechanistic sense because these genes
may be collectively involved in the pathogenesis of EH
through the same detoxification pathway.
It is known that cigarette smoking is a model of chronic
AHR activation in humans [65]. Notably, a majority of
interaction models identified by MDR included cigarette
smoking as a covariate, indicating an importance of
gene–environment interactions for the penetration of
hypertension phenotype. The best gene–smoking MB-
MDR interaction model associated with EH risk com-
prised cigarette smoking and CYP1A1, CYP1A2, and
CYP1B1. Furthermore, MDR analysis stratified by smok-
ing status enabled the identification of specific SNPs
combinations influencing hypertension susceptibility in
exposed and unexposed individuals. Interactions between
ARNT, CYP1A1, CYP1A2, and CYP1B1 were significantly
associated with disease susceptibility in smokers, whereas
ARNT, AHRR, CYP1B1, and NQO1 gene polymorphisms
contributed toward the disease in nonsmokers. Differences
in the spectrum of interacted genes between smokers and
nonsmokers apparently reflect that the molecular
mechanisms by which AHR pathway SNPs contribute
toward hypertension may be distinguished considerably
depending on whether the individual is exposed or not
exposed to PAHs. It is permissible to assume that the
mechanisms of hypertension in smoker individuals are
related to an enhanced metabolic activation of PAHs by
the CYP1 family of enzymes such as 1A1, 1A2, and 1B1.
For instance, a carriage of common ‘high-risk genotype’
combinations such as CYP1A1 462II×CYP1B1 432VV and
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AHR 554RR×CYP1A1 462II×CYP1A2 164AA×CYP1B1
432VV (Supplementary Table 5, Supplemental digital
content 5, http://links.lww.com/FPC/B138, A) in cigarette
smokers could promote xenobiotics’ toxification (the con-
version of a chemical compound into a more toxic form than
a parent molecule). In contrast, a carriage of common gen-
otype combinations, for example, ARNT 567CC×CYP1A2
164CC, CYP1A1 462II×CYP1A2 164CC×CYP1B1 432VL
or ARNT 567CC×CYP1A1 462II×CYP1A2 164CC
(Supplementary Table 5, Supplemental digital content 5,
http://links.lww.com/FPC/B138, A) is associated with a
decreased EH risk. This association may be explained by
decreased activation of the AHR cascade and CYP1A2
induction in PAH-exposed individuals (‘low-activity geno-
types’ 567CC and 164CC are associated with decreased
mRNA levels of ARNT and CYP1A2, respectively).
The allele 462Val of the CYP1A1 gene is known to be
associated with a significant increase in the enzyme activity
and induction [66]. In this context, it is unclear why genotype
462IV showed a protective effect against EH risk even in the
carriers of ‘high-risk genotypes’ such as CYP1A2 164AA or
CYP1B1 432VV. It should be noted that a similar ‘protective
effect’ of allele 462Ile CYP1A1 was found against the risk of
lung cancer [67,68]. An interesting finding is that nonsmoker
individuals with the most common genotype combination,
that is, ARNT 567CG×CYP1A2 164AC, were at a higher risk
of EH. Apparently, a carriage of these ‘high-activity geno-
types’ (Fig. 4 and Supplementary Table 6, Supplemental
digital content 6, http://links.lww.com/FPC/B139) promotes an
enhanced activation of the AHR cascade and, therefore, the
increased risk of hypertension could be related to
CYP1A2-mediated cardiovascular toxicity because of an
exposure to the background levels of PAHs present in the
environment. In nonsmokers, the protective effects of geno-
type combinations AHRR 185PA×ARNT 567CC×CYP1B1
432VV and AHRR 185PA×ARNT 567GG×CYP1B1 432LL
against hypertension risk can be explained by the fact that
‘the high-activity’ of genotype CYP1B1 432VV could be
compensated by ‘the low-activity’ of genotype ARNT 567CC
and vice versa, thus decreasing AHR pathway activation and
associated cardiovascular toxicity.
The present study has some limitations. A majority of the
associations of AHR pathway SNPs with hypertension
susceptibility were not strong, thereby showing small-to-
modest effects of these genes on disease phenotype. The
study focused only on major XMEs genes regulated by
the pathway, whereas genes under transcriptional reg-
ulation from the AHR-ARNT heterodimer also include at
least GSTA2, UGT1A1, UGT1A6, and NFE2L2 [35,69].
Because not all AHR pathway SNPs were selected for
this study, our findings do not allow any definitive con-
clusion to be made as yet on the comprehensive con-
tribution of the genes toward hypertension susceptibility.
It is safe to assume that the simultaneous examination of
all tag-SNPs within these genes may provide more
comprehensive genetic profiling of the AHR pathway in
EH. Therefore, the hypothesis that AHR pathway genes
are collectively involved in the molecular basis of EH
requires further confirmation in other studies. Nevertheless,
on the basis of the study findings, it is plausible to assume
that individuals with increased activity of the AHR cascade
and enhanced toxification of xenobiotics are at increased risk
for EH related to PAH exposure. Undoubtedly, a complete
understanding of the causative role of environmental PAHs
in the development of hypertension will require more
experimental and clinical studies to answer the question of
whether the toxicogenomic mechanisms are an important
part of disease pathogenesis.
Although the exact role of AHR signaling in the regulation of
BP remains to be elucidated, undoubtedly, the pathway
could serve as a target in the treatment and prevention of
hypertension and related diseases. In particular, pharmacolo-
gical approaches that antagonize the AHR signaling pathway
with a focus on the adverse effects of toxic AHR-ligands
could decrease cardiovascular toxicity and benefit patients
with hypertension and associated diseases. For instance,
Resveratrol, a dietary antioxidant supplement with a natural
substance, would be a potential candidate as a means of
prevention of AHR-mediated toxicity of smoking and envir-
onmental pollution on a widespread scale [65]. Further eco-
logical and pharmacological genomics studies are required to
provide deeper insights into the roles of the AHR pathway
genes in responses to environmental xenobiotics and will
identify effective therapeutic options for the management of
hypertension at population and individual levels.
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